CytomX Therapeutics (CTMX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.09
- Estimate
- -$0.11
- Surprise
- +14.6%
- Revenue (period 2026-06-30)
- $1.4M
- Score today
- 4.0/10
Revenue source: xbrl.
How the report landed
CytomX Therapeutics (CTMX) reported a narrower loss than forecast — diluted EPS of -$0.09 against the -$0.11 estimate (a 14.6% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CTMX Sell at 4.0/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +14.6% surprise compares with a -57.2% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: Varseta-M
- DATA_ISSUE: analyst_target_implausible (raw $12.25 vs price $3.71 — ratio 3.3×). Rejected, falling back to technical TP.
- Quality below floor (3.1 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.71
- Price target
- $3.80
- Stop
- $3.45
- Upside to target
- +2.4%
Model outputs from TrendMatrix’s engine as of 2026-09-06 — shown for context, not personalized investment advice.
CTMX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $808.4M
- P/E (fwd)
- -7.8
- 52-week range
- $1.90–$8.21
- Off 52-week high
- 54.8%
- RSI (14)
- 58
- Volume vs avg
- 0.75×
- Score today
- 4.0/10